Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and β2-microglobulin changes

NeuroSignals

Volumn 14, Issue 3, 2005, Pages 126-135

  Kepplinger, Berthold ^a,b   Baran, Halina ^c   Kainz, Astrid ^a,b   Ferraz Leite, Heber ^d   Newcombe, Jea ^e   Kalina, Pavol ^b  

^a General Hospital   (Austria)

^b Neuropsychiatric Hospital   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

2 microglobulin; Ageing; Cerebrospinal fluid; IgG; Kynurenic acid

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; KYNURENIC ACID; KYNURENINE AMINOTRANSFERASE;

ADULT; AGED; AGING; ANALYTICAL PARAMETERS; ANTIBODY DETECTION; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOREGULATION; MALE; NEUROCHEMISTRY; PROBABILITY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; RADIOENZYMATIC ASSAY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGING; ANALYSIS OF VARIANCE; BETA 2-MICROGLOBULIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; KYNURENIC ACID; LINEAR MODELS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; TRANSAMINASES;

EID: 23844467167     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086295     Document Type: Article

References (68)

1. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
2. Meldrum B, Garthwaite J: Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
3. Bartus RT: On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000;163:495-529.
4. Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309-379.
5. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: Physiopathological implications. J Neurosci 2001;21:7463-7473.
6. Foster AC, Vezzani A, French ED, Schwarcz R: Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 1984;48:273-278.
7. Stone TW: Kynurenines in the CNS: From endogenous obscurity to therapeutic importance. Prog Neurobiol 2001;64:185-218.
8. Baran H, Jellinger K, Deecke L: Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999;106:165-181.
9. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S: Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992;42:1702-1706.
10. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED: Kynurenine pathway measurements in Huntington's disease striatum. Evidence for reduced formation of kynurenic acid. J Neurochem 1990;55:1327-1339.
11. Connick JH, Carla V, Moroni F, Stone TW: Increase in kynurenic acid in Huntington's disease motor cortex. J Neurochem 1989;52:958-987.
12. Jauch D, Urbanska EM, Guidetti P, Bird ED, Vonsattel JPG, Whetsell Jr WO, Schwarcz R: Dysfunction of brain kynurenic acid metabolism in Huntington's disease: Focus on kynurenine aminotransferases. J Neurol Sci 1995;130:39-47.
13. 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 1992;40:71-80.
14. Fuchs D, Dotevall L, Hagberg L, Werner ER, Wachter H: Kynurenine in cerebrospinal fluid of patients with Lyme neuroborreliosis. Immunol Infect Dis 1991;1:271-274.
15. Baran H, Schwarcz R: Regional differences in the ontogenetic pattern of kynurenine aminotransferase in the rat brain. Dev Brain Res 1993;74:283-286.
16. Beal MF, Swartz KJ, Isacson O: Developmental changes in brain kynurenic acid concentrations. Dev Brain Res 1992;68:136-139.
17. Gramsbergen JBP, Schmidt W, Turski WA, Schwarcz R: Age-related changes in kynurenic acid production in rat brain. Brain Res 1992;588:1-5.
18. Moroni F, Russi P, Lombardi G, Beni M, Carla V: Presence of kynurenic acid in the mammalian brain. J Neurochem 1988;51:177-180.
19. Hlinak Z, Krejci I: Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats. Psychopharmacology 1995;120:463-469.
20. Steele RJ, Stewart MG: 7-Chlorokynurenate, an antagonist of the glycine binding site on the NMDA receptor, inhibits memory formation in day-old chicks (Gallus domesticus). Behav Neural Biol 1993;60:89-92.
21. Baran H, Cairns N, Lubec B, Lubec G: Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with DOWN syndrome. Life Sci 1996; 58:1891-1899.
22. Birch PJ, Grossman CJ, Hayes AG: Kynurenic acid antagonizes responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988;154:85-87.
23. Frohman EM, Frohman TC, Dustin ML, Vayuvegula B, Choi B, Gupta A, van den Noort S, Gupta S: The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-gamma, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: Relevance to intracerebral antigen presentation. J Neuroimmunol 1989;23:117-124.
24. Saito K, Markey SP, Heyes MP: Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 1992;1:25-39.
25. Morganti-Kossmann MC, Kossmann T, Wahl SM: Cytokines and Neuropathology. TIPS 1992;13:286-291.
26. Benveniste EN: Astrocyte-microglia interactions; in Murphy S (ed): Astrocytes: Pharmacology and Function. San Diego, Academic Press, 1993, pp 355-382.
27. Byrne G, Lehmann LK, Kischbaum JG, Borden EC, Lee CM, Brown RR: Induction of tryptophan degradation in vitro and in vivo: A gamma-interferon stimulated activity. J Interferon Res 1986;6:389-398.
28. Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibneger G, Szabo G, Dierich M, Wachter H: Human macrophages degrade tryptophan upon induction by interferon gamma. Life Sci 1987;42:310-316.
29. Lamelin JP, Vincent C, Fontaine-Legrand C, Revillard JP: Elevation of serum beta 2-microglobulin levels during infections mononucleosis. Clin Immunol Immunopathol 1982;24:55-62.
30. Nilsson K, Evrin PE, Welsh KI: Production of beta 2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transpl Rev 1974;21:53-84.
31. Martinez M, Frank A, Hernanz A: Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid od patients with dementia of the Alzheimer type. J Neuroimmunol 1993;48:235-240.
32. Tenhunen R, Iivanainen M, Kovanen J: Cerebrospinal fluid beta 2-microglobulin in neurological disorders. Acta Neurol Scand 1978;58:366-373.
33. 2-microglobulin in patients infected with human immunodeficiency virus. Neurology 1989;39:830-834.
34. Tibbling G, Link H, Öhman S: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-390.
35. Olsson T, Kostulas V, Link H: Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem 1984;30:1246-1249.
36. Shibata K: Fluorimetric microdetermination of kynurenic acid, an endogenous blocker of neurotoxicity, by high performance liquid chromatography. J Chromat 1988;430:376-380.
37. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF: Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode assay detection. Analyt Biochem 1990;85:363-376.
38. Turski WA, Gramsbergen JBP, Traitler H, Schwarcz R: Rat brain slices produce and liberate kynurenic acid upon expose to L-kynurenine. J Neurochem 1989;52:1629-1636.
39. 3H]kynurenine as a substrate. Neuroscience 1993;55:177-184.
40. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling A, Elia J, Kruesi MJP, Lackner A, Larsen SA, Lee K, Leonard HL, Markey SP, Martin A, Milstein S, Mouradian MM, Pranzatelli MR Quearry BJ, Salazar A, Smith M, Strauss SE, Sunderland T, Swedo SW, Tourtellotte WW: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992;115:1249-1273.
41. Rust RS Jr, Dodson WE, Trotter JL: Cerebrospinal fluid IgG in childhood: The establishment of reference value. Ann Neurol 1988;23: 406-410.
42. Walker DW, Curtis B, Lacey B, Nitsos I: Kynurenic acid in brain and cerebrospinal fluid of fetal, new born, and adult sheep and effects of placental emboliation. PediatriC Res 1999;45:820-826.
43. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313:96-98.
44. Rejdak K, Bartosik-Psujek H, Dobosz B, Kocki T, Grieb P, Giovannoni G, Turski WA, Stelmasiak Z: Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett 2002;331:63-65.
45. Heyliger SO, Goodman CB, Ngong JM, Soliman KFA: The analgesic effects of tryptophan and its metabolites in the rat. Pharmacol Res 1998;38:243-250.
46. Schwieler L, Erhardt S, Erhardt C, Engberg G: Prostaglandine-mediated control of rat brain kynurenic acid synthesis - opposite actions by COX-1 and COX-2 isoforms. J Neural Transm DOI 10.1007/s00702-004-0231-y.
47. Schwarcz R, Baran H, Wu H-Q, Du F, McMaster O: The Neurochemistry of quinolinic acid and kynurenate: Current Concepts; in Meldrum BS, Moroni F, Simon RP, Woods JH (eds): Excitatory Amino Acids. New York, Raven Press, 1991, pp 365-375.
48. Sharfman HE, Goodman JH, Schwarcz R: Eletrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: in vivo and in vitro. Amino Acids 2000;19:283-297.
49. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem 1991;56:2007-2015.
50. Garton MJ, Keir G, Lakshmi MV, Thompson EJ: Age-related changes in cerebrospinal fluid protein concentrations. J Neurol Sci 1991;104:74-80.
51. Gal EM, Sherman AD: L-Kynurenine: Its synthesis and possible regulatory function in brain. Neurochem Res 1980;5:223-239.
52. Wada H, Ito H, Orimo H, Sato A: Kynurenine specifically increases in the cerebrospinal fluid of the aged rats. Biog Amines 1994;3:221-225.
53. Heyes MP, Saito K, Markey SP: Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 1992;283:633-635.
54. Heyes MP, Chen CY, Major EO, Saito K: Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997;326:351-356.
55. Okuno E, Nakamura M, Schwarcz R: Two kynurenine aminotransferases in human brain. Brain Res 1991;542:307-312.
56. Baran H, Okuno E, Kido R, Schwarcz R: Purification and characterisation of kynurenine aminotransferase I from human brain. J Neurochem 1994;62:730-738.
57. Roberts RC, Du F, McCarthy KE, Okuno E, Schwarcz R: Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: A light and electron microscopic study. J Comp Neurol 1992;326:82-90.
58. Tamburin M, Mostardini M, Benatti L: Kynurenine aminotransferase I (KAT I) isoform gene expression in the rat brain: An in situ hybridization study. Neuroreport 1999;10:61-65.
59. Baran H, Kepplinger B, Kainz A, Draxler M, Ferraz-Leite H, Wallner J, Newcombe J, Erhart H: Kynurenine aminotransferases in human cerebro-spinal fluid. J Neurol 2003;250(suppl 2):II/10, 4.
60. Ferraro TN, Hare TA: Free and conjugated amino acids in human CSF: Influence of age and sex. Brain Res 1985;338:53-60.
61. Sloane JA, Hollander W, Moss MB, Rosene DL, Abraham CR: Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol Aging 1999;20:395-405.
62. Laping NJ, Teter B, Nichols NR, Rozovsky I, Finch CE: Glial fibrillary acidic protein: Regulation by hormones, cytokines, and growth factors. Brain Pathol 1994;4:259-275.
63. Lee G, Dallas S, Hong M, Bendayan R: Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 2001;53:569-596.
64. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P: Alzheimer's disease - synergistic effects of glucose deficit, oxydative stress and advanced glycation endproducts. J Neural Transm 1998;105:439-461.
65. Morgan TE, Rozovsky I, Golgsmith SK, Stone DJ, Yoshida T, Finch CE: Increased transcription of the astrocyte gene GFAP during middle-age is attenuated by food restriction: Implications for the role of oxidative stress. Free Radic Biol Med 1997;23:524-528.
66. Magnusson KR: Aging of glutamate receptors: Correlation between binding and spatial memory performance in mice. Mech Ageing Dev 1998;104:227-248.
67. Magnusson KR, Cotman CW: Effects of aging on NMDA and MK801 binding sites in mice. Brain Res 1993;604:334-337.
68. Kumoro H, Rakic P: Modulation of neuronal migration by NMDA receptors. Science 1993;260:95-97.